EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

Vivian Lee, Qishi Zheng, Desiree-Faye Toh, Chee Jian Pua, Jennifer A Bryant, Chi-Hang Lee, Stuart A Cook, Javed Butler, Javier Díez, A Mark Richards, Thu-Thao Le, Calvin W L Chin

Frontiers in Cardiovascular Medicine · 22.08.2023 · 10

DOI: 10.3389/fcvm.2023.1248468 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 22.08.2023. Verfasst von Vivian Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Heart Research Institute Singapore (NHRIS), National Heart Centre Singapore, Singapore, Singapore. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor–neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure, signifying a multifactorial mode of action beyond hemodynamic regulation. We aim to test the hypothesis that compared with angiotensin II receptor blockade (ARB) alone, ARNi is more effective in regressing diffuse interstitial myocardial fibrosis in HHD.

Methods

Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH) is a prospective, randomized, open-label, blinded endpoint (PROBE) clinical trial. Adults with hypertension and left ventricular hypertrophy (LVH) according to Asian sex- and age-specific thresholds on cardiovascular magnetic resonance (CMR) imaging are randomized to treatment with either sacubitril/valsartan (an ARNi) or valsartan (an ARB) in 1:1 ratio for a duration of 52 weeks, at the end of which a repeat CMR is performed to assess differential changes from baseline between the two groups. The primary endpoint is the change in CMR-derived diffuse interstitial fibrosis volume. Secondary endpoints include changes in CMR-derived left ventricular mass, volumes, and functional parameters. Serum samples are collected and stored to assess the effects of ARNi, compared with ARB, on circulating biomarkers of cardiac remodeling. The endpoints will be analyzed with reference to the corresponding baseline parameters to evaluate the therapeutic effect of sacubitril/valsartan vs. valsartan.

Discussion

REVERSE-LVH will examine the anti-fibrotic potential of sacubitril/valsartan and will offer mechanistic insights into the clinical benefits of sacubitril/valsartan in hypertension in relation to cardiac remodeling. Advancing the knowledge of the pathophysiology of HHD will consolidate effective risk stratification and personalized treatment through a multimodal manner integrating complementary CMR and biomarkers into the conventional care approach. Clinical Trial Registration : ClinicalTrials.gov , identifier, NCT03553810.

Schlagwörter

Stichwörter der Autor:innen

ARNibiomarkerscardiovascular magnetic resonance imagingheart failurehypertensive heart diseasemyocardial fibrosissacubitril/valsartan

Autor:innen und Institutionen

  • National Heart Research Institute Singapore (NHRIS), National Heart Centre Singapore, Singapore, Singapore.
  • Cochrane Singapore, Singapore, Singapore.
  • Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.
  • Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore.
  • Cardiovascular & Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore.
  • Baylor Scott and White Research Institute, Dallas, TX, United States.

Zitieren

APA

Lee, V., Zheng, Q., Toh, D. F., Pua, C. J., Bryant, J. A., Lee, C. H., Cook, S. A., Butler, J., Díez, J., Richards, A. M., Le, T. T., & Chin, C. W. L. (2023). Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1248468

Vancouver

Lee V, Zheng Q, Toh DF, Pua CJ, Bryant JA, Lee CH, et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1248468

BibTeX
@article{Lee2023,
  author = {Lee, Vivian and Zheng, Qishi and Toh, Desiree-Faye and Pua, Chee Jian and Bryant, Jennifer A and Lee, Chi-Hang and Cook, Stuart A and Butler, Javed and Díez, Javier and Richards, A Mark and Le, Thu-Thao and Chin, Calvin W L},
  title = {Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fcvm.2023.1248468}
}
Kostenlos starten →